Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GRN | P28799 | 1/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12221255 | 0.82 | SMN1; SMN2 (0.45) | ALDH1A1SMN1; SMN2L3MBTL1HTTGRN | |
| SCHEMBL12221241 | 0.81 | ACHE (0.58) | ALDH1A1SMN1; SMN2L3MBTL1HTTGRN | |
| SCHEMBL15143106 | 0.81 | SMN1; SMN2 (0.44) | ALDH1A1SMN1; SMN2L3MBTL1HTTGRN | |
| SCHEMBL24340341 | 0.81 | SMN1; SMN2 (0.44) | ALDH1A1SMN1; SMN2L3MBTL1HTTGRN | |
| SCHEMBL1506111 | 0.81 | SMN1; SMN2 (0.44) | ALDH1A1SMN1; SMN2L3MBTL1HTTGRN | |
| Bromide SCHEMBL16212289 | 0.79 | SMN1; SMN2 (0.43) | ALDH1A1SMN1; SMN2L3MBTL1HTTGRN | |
| SCHEMBL2558328 | 0.78 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2L3MBTL1HTTGRN | |
| SCHEMBL17570796 | 0.78 | SMN1; SMN2 (0.46) | ALDH1A1SMN1; SMN2L3MBTL1HTTGRN | |
| SCHEMBL368970 | 0.78 | — | — | |
| SCHEMBL28147463 | 0.77 | VNN1 (0.49) | ALDH1A1SMN1; SMN2L3MBTL1HTTGRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747249-A1 | TREM2 MODULATORS | Muna Therapeutics ApS (DK) | 2026-05-27 | — | — | EP | disclosed |
| US-12459953-B2 | TREM2 modulators | MUNA THERAPEUTICS APS (DK) | 2025-11-04 | — | — | US | disclosed |
| US-20250223294-A1 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2025-07-10 | — | — | US | disclosed |
| EP-4551575-A2 | TREM2 MODULATORS | Muna Therapeutics ApS (DK) | 2025-05-14 | — | — | EP | disclosed |
| CN-119403806-A | TREM2 modulators | 穆纳治疗有限公司 | 2025-02-07 | — | — | CN | disclosed |
| WO-2025017059-A1 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2025-01-23 | — | — | WO | disclosed |
| US-20240309003-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| EP-4334295-A2 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | Vigil Neuoscience, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117597333-A | Heterocyclic compounds as receptor 2-triggering agonists expressed on myeloid cells and methods of use | 维吉尔神经科学股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2024008722-A2 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2024-01-11 | — | — | WO | disclosed |
| US-11028093-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3227297-B1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200291039-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-10730880-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC | 2020-02-20 | — | — | US | disclosed |
| US-20190177328-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-10189845-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3227297-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016090285-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459953-B2 | TREM2 modulators | FCER2, MERTK, FCGR1A | ALDH1A1 4399/4885SMN1; SMN2 188/4885L3MBTL1 3602/4885 |
| US-20200291039-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | ALDH1A1 1526/4885SMN1; SMN2 4032/4885L3MBTL1 559/4885 |
| US-10730880-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors | JAK1, JAK3, JAK2 | ALDH1A1 1526/4885SMN1; SMN2 4032/4885L3MBTL1 559/4885 |
| US-20190177328-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | ALDH1A1 1526/4885SMN1; SMN2 4032/4885L3MBTL1 559/4885 |
| US-20240309003-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | ALDH1A1 2654/4885SMN1; SMN2 472/4885L3MBTL1 4809/4885 |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | ALDH1A1 1526/4885SMN1; SMN2 4032/4885L3MBTL1 559/4885 |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | ALDH1A1 3241/4885SMN1; SMN2 1094/4885L3MBTL1 1495/4885 |
| US-10189845-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | JAK1, JAK3, JAK2 | ALDH1A1 1526/4885SMN1; SMN2 4032/4885L3MBTL1 559/4885 |
| US-11028093-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | JAK1, JAK3, JAK2 | ALDH1A1 1526/4885SMN1; SMN2 4032/4885L3MBTL1 559/4885 |
| US-20250223294-A1 | TREM2 MODULATORS | FCER2, MERTK, FCGR1A | ALDH1A1 4399/4885SMN1; SMN2 188/4885L3MBTL1 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.